1
|
de Mazancourt P, Quélin F, Flaujac C, de Raucourt E, Guillet B, Bauduer F, Ernest V, Beurrier P, Avril A, d'Oiron R, Biron-Andréani C, Meunier S, Dargaud Y. A focus on dominant negative variants in a series of 170 heterozygous FXI-deficient patients. Haemophilia 2023. [PMID: 37252892 DOI: 10.1111/hae.14802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Revised: 05/11/2023] [Accepted: 05/11/2023] [Indexed: 06/01/2023]
Abstract
INTRODUCTION Dominant-negative effects have been described for 10 F11 variants in the literature. AIM The current study aimed at identifying putative dominant-negative F11 variants. MATERIAL AND METHODS This research consisted in a retrospective analysis of routine laboratory data. RESULTS In a series of 170 patients with moderate/mild factor XI (FXI) deficiencies, we identified heterozygous carriers of previously reported dominant-negative variants (p.Ser243Phe, p.Cys416Tyr, and p.Gly418Val) with FXI activities inconsistent with a dominant-negative effect. Our findings also do not support a dominant-negative effect of p.Gly418Ala. We also identified a set of patients carrying heterozygous variants, among which five out of 11 are novel, with FXI activities suggesting a dominant-negative effect (p.His53Tyr, p.Cys110Gly, p.Cys140Tyr, p.Glu245Lys, p.Trp246Cys, p.Glu315Lys, p.Ile421Thr, p.Trp425Cys, p.Glu565Lys, p.Thr593Met, and p.Trp617Ter). However, for all but two of these variants, individuals with close to half normal FXI coagulant activity (FXI:C) were identified, indicating an inconstant dominant effect. CONCLUSION Our data show that for some F11 variants recognized has having dominant-negative effects, such effects actually do not occur in many individuals. The present data suggest that for these patients, the intracellular quality control mechanisms eliminate the variant monomeric polypeptide before homodimer assembly, thereby allowing only the wild-type homodimer to assemble and resulting in half normal activities. In contrast, in patients with markedly decreased activities, some mutant polypeptides might escape this first quality control. In turn, assembly of heterodimeric molecules as well as mutant homodimers would result in activities closer to 1:4 of FXI:C normal range.
Collapse
Affiliation(s)
- Philippe de Mazancourt
- UMR1179, Université de Versailles-Saint-Quentin, Montigny le Bretonneux, France
- Laboratoire de Biologie Moléculaire, Hôpital A. Paré, APHP.Paris-Saclay, Boulogne-Billancourt, France
| | - Florence Quélin
- Département de Recherche Clinique, CH Versailles, Le Chesnay, France
| | - Claire Flaujac
- Laboratoire de biologie médicale, secteur hémostase, centre hospitalier de Versailles (André Mignot), Le Chesnay, France
| | - Emmanuelle de Raucourt
- Centre de Ressources et de Compétences Maladies Hémorragiques Constitutionnelles, CH de Versailles, Le Chesnay, France
| | - Benoît Guillet
- Centre de Traitement des maladies hémorragiques, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France
| | - Frédéric Bauduer
- Service d'Hématologie, Centre Hospitalier de la Côte Basque, Bayonne, and UMR 5199 PACEA, Université de Bordeaux, Pessac, France
| | - Vincent Ernest
- Laboratoire d'Hématologie, CHU la Timone, Marseille, France
| | | | - Aurélie Avril
- UMR1179, Université de Versailles-Saint-Quentin, Montigny le Bretonneux, France
| | - Roseline d'Oiron
- Centre de Traitement de l'Hémophilie - CRTH - CHU Paris-Sud - Hôpital de Bicêtre, APHP.Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Christine Biron-Andréani
- Centre de Traitement de l'Hémophilie (CTH) Centre de Ressources et de Compétences Maladies Hémorragiques Constitutionnelles (CRC-MHC) - Hôpital St-Eloi, CHU Montpellier, Montpellier, France
| | - Sandrine Meunier
- Hospices civils de Lyon; Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, CHU de Lyon, Lyon, France
| | - Yesim Dargaud
- Hospices civils de Lyon; Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, CHU de Lyon, Lyon, France
| |
Collapse
|
2
|
Zhang D, Zhang X, Sun B, Li H, Xue F, Liu X, Sun H, Chen L, Qin L, Lin Y, Zhang L, Ru K, Yang R. Molecular analysis in 12 factor XI deficiency patients from China: Identification of three novel splicing mutations. Thromb Res 2020; 192:100-102. [PMID: 32464451 DOI: 10.1016/j.thromres.2020.05.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 05/01/2020] [Accepted: 05/18/2020] [Indexed: 10/24/2022]
Affiliation(s)
- Donglei Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China; Tianjin Sino-US Diagnostics Co., Ltd., Tianjin, PR China
| | - Xian Zhang
- The Hematology Department of Zhongnan Hospital of Wuhan University, Wuhan City, Hubei, PR China
| | - Boyang Sun
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China; CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, PR China; Tianjin Laboratory of Blood Disease Gene Therapy, Tianjin, PR China
| | - Huiyuan Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China; CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, PR China; Tianjin Laboratory of Blood Disease Gene Therapy, Tianjin, PR China
| | - Feng Xue
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China
| | - Xiaofan Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China
| | - Haiyan Sun
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China
| | - Long Chen
- Tianjin Sino-US Diagnostics Co., Ltd., Tianjin, PR China
| | - Li Qin
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China; Tianjin Sino-US Diagnostics Co., Ltd., Tianjin, PR China
| | - Yani Lin
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China; Tianjin Sino-US Diagnostics Co., Ltd., Tianjin, PR China
| | - Lei Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China; CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, PR China; Tianjin Laboratory of Blood Disease Gene Therapy, Tianjin, PR China
| | - Kun Ru
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China; Tianjin Sino-US Diagnostics Co., Ltd., Tianjin, PR China.
| | - Renchi Yang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, PR China; CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, PR China; Tianjin Laboratory of Blood Disease Gene Therapy, Tianjin, PR China.
| |
Collapse
|
3
|
Shao Y, Cao Y, Lu Y, Dai J, Ding Q, Wang X, Xi X, Wang H. Clinical manifestations and mutation spectrum of 57 subjects with congenital factor XI deficiency in China. Blood Cells Mol Dis 2016; 58:29-34. [PMID: 27067486 DOI: 10.1016/j.bcmd.2016.01.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 01/12/2016] [Accepted: 01/15/2016] [Indexed: 11/23/2022]
Abstract
Congenital factor XI (FXI) deficiency is a rare bleeding disorder with unpredictable bleeding tendency. Few studies in a large cohort have been reported regarding associations between FXI activity (FXI:C) or genotypes and bleeding symptoms currently. This study characterized clinical manifestations and mutation spectrum of 57 subjects with FXI deficiency in China. Clinical data were collected and mutations were identified by direct sequencing and determined by mRNA analysis. The result revealed bleeding symptoms were only found in 12 patients (12/57, 21.1%) with severely reduced FXI:C, and prolonged bleeding post injury/surgery as well as easy bruising were the commonest bleeding manifestations presented in respective 5 cases (5/12, 41.7%). A total number of 37 mutations were identified including 19 missense mutations, 9 nonsense mutations, 6 splice site mutations and 3 small deletions. Among them, 4 missense mutations, 5 splice mutations, 3 small deletions and a nonsense mutation were newly detected. W228*, G400V, Q263* and c.1136-4delGTTG with a total frequency of 48.3% were the most four common mutations in Chinese patients. RT-PCR analysis was carried out and confirmed that both c.596-8T>A and c.1136-4delGTTG were pathogenic due to frameshift resulting in respective truncated proteins. Our findings suggested clinical manifestations had little to do with FXI:C or genotypes, which required further study. This study, the largest investigation of FXI deficiency in China revealed that the F11 mutation spectrum of Chinese population was distinct from those of other populations earlier established.
Collapse
|
4
|
Lee JH, Cho HS, Hyun MS, Kim HY, Kim HJ. A novel missense mutation Asp506Gly in Exon 13 of the F11 gene in an asymptomatic Korean woman with mild factor XI deficiency. Ann Lab Med 2011; 31:290-3. [PMID: 22016685 PMCID: PMC3190010 DOI: 10.3343/kjlm.2011.31.4.290] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2011] [Revised: 05/02/2011] [Accepted: 07/01/2011] [Indexed: 11/19/2022] Open
Abstract
Factor XI (FXI) deficiency is a rare autosomal recessive coagulation disorder most commonly found in Ashkenazi and Iraqi Jews, but it is also found in other ethnic groups. It is a trauma or surgery-related bleeding disorder, but spontaneous bleeding is rarely seen. The clinical manifestation of bleeding in FXI deficiency cases is variable and seems to poorly correlate with plasma FXI levels. The molecular pathology of FXI deficiency is mutation in the F11 gene on the chromosome band 4q35. We report a novel mutation of the F11 gene in an 18-year-old asymptomatic Korean woman with mild FXI deficiency. Pre-operative laboratory screen tests for lipoma on her back revealed slightly prolonged activated partial thromboplastin time (45.2 sec; reference range, 23.2-39.4 sec). Her FXI activity (35%) was slightly lower than the normal FXI activity (reference range, 50-150%). Direct sequence analysis of the F11 gene revealed a heterozygous A to G substitution in nucleotide 1517 (c.1517A>G) of exon 13, resulting in the substitution of aspartic acid with glycine in codon 506 (p.Asp506Gly). To the best of our knowledge, the Asp506Gly is a novel missense mutation, and this is the first genetically confirmed case of mild FXI deficiency in Korea.
Collapse
Affiliation(s)
- Jong Ho Lee
- Department of Laboratory Medicine, Yeungnam University College of Medicine, Daegu, Korea
| | - Hee Soon Cho
- Department of Laboratory Medicine, Yeungnam University College of Medicine, Daegu, Korea
| | - Myung Soo Hyun
- Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea
| | - Hwa-Young Kim
- Department of Biochemistry & Molecular Biology, Yeungnam University College of Medicine, Daegu, Korea
| | - Hee-Jin Kim
- Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea
| |
Collapse
|